Original ArticlesDiclofenac Is Associated With a Reduced Incidence of Post–Endoscopic Retrograde Cholangiopancreatography Pancreatitis: Results From a Danish Cohort StudyLeerhøy, Bonna BSN*; Nordholm-Carstensen, Andreas MD*; Novovic, Srdan MD†; Hansen, Mark Berner MD, DMSc*‡; Jørgensen, Lars Nannestad MD, DMSc*Author Information From the *Digestive Disease Center, Bispebjerg Hospital, University of Copenhagen, Copenhagen; †Department of Gastroenterology and Surgical Gastroenterology, Hvidovre Hospital, University Hospital Hvidovre, Hvidovre, Denmark; and ‡AstraZeneca Research and Development, Mölndal, Sweden. Received for publication September 21, 2013; accepted April 8, 2014. Reprints: Bonna Leerhøy, BSN, Department of Surgery, Bispebjerg Hospital, University of Copenhagen, Bispebjerg Bakke 23, DK-2400 Copenhagen NV, Denmark (e-mail: firstname.lastname@example.org). This study was supported by grants from the Board of Directors of Bispebjerg Hospital, University of Copenhagen, and the Digestive Disease Center, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark. The authors declare no conflict of interest. Pancreas: November 2014 - Volume 43 - Issue 8 - p 1286-1290 doi: 10.1097/MPA.0000000000000169 Buy Metrics Abstract Objective The aim of this study was to assess the clinical effect of diclofenac administered as a single dose for the prevention of postprocedure pancreatitis in a consecutive series of patients who had undergone endoscopic retrograde cholangiopancreatography (ERCP). Methods Patients with a native papilla Vateri subjected to ERCP during 2010 (control group, n = 218) and 2012 (diclofenac group, n = 182) were included. Patients with a history of chronic pancreatitis or recent acute pancreatitis were excluded. From January 2012, a rectal suppository containing 100 mg of diclofenac was administered immediately after endoscopy in all patients. The primary outcome of post-ERCP pancreatitis was assessed retrospectively by reviewing the patients’ charts. Results The overall incidence of post-ERCP pancreatitis was 32 (14.7%) of the 218 patients in the control group and 9 (4.9%) of the 182 patients in the diclofenac group (P = 0.002). Moderate to severe pancreatitis occurred in 22 (10.1%) of the 218 patients in the control group versus 8 (4.4%) of the 182 patients in the diclofenac group (P = 0.036). Conclusions This controlled cohort study suggests that the implementation of a single dose of 100 mg of diclofenac rectally administered significantly reduces the incidence of post-ERCP pancreatitis in an unselected material of patients with native papilla. © 2014 by Lippincott Williams & Wilkins.